Company Overview
Harvard Bioscience, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it develops, manufactures, and sells technologies, products, and services for life science applications across the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company's product portfolio includes cellular and molecular technology products, such as syringe and peristaltic pumps, which are essential tools for research and development in scientific laboratories. With a market capitalization of $21.78M and a workforce of 316 employees, the firm maintains a modest operational scale relative to large-cap peers in the biotechnology and medical device space. This market cap and revenue profile indicates that the company is a small-cap entity, suggesting it may have less liquidity and higher volatility than larger counterparts, while its international presence implies exposure to global demand for life science infrastructure rather than reliance solely on a domestic market.
Financial Health
The company reported a trailing twelve-month revenue of $86.55M alongside a net income of -$56,700,000 and an EBITDA of $7.44M. The significant gap between the positive revenue and substantial negative net income reveals a cost structure where operating expenses, likely including research and development, administrative costs, or stock-based compensation, heavily outweigh the gross profits generated from sales. Despite the net loss, the firm generated $10.11M in free cash flow, which provides a critical buffer for financial flexibility, allowing management to fund operations, invest in new technologies, or reduce debt without immediate external financing. The company's profitability is further illuminated by three distinct margin metrics: a gross margin of 57.7% indicates strong pricing power or low cost of goods sold, an operating margin of 14.0% suggests that operational efficiencies are being maintained despite high overheads, and a profit margin of -65.5% confirms that non-operating expenses or other charges are eroding bottom-line profitability. On the balance sheet, Harvard Bioscience holds $8.61M in cash against $44.28M in debt, resulting in a debt-to-equity ratio of 322.39, which characterizes a leveraged balance sheet where equity is significantly smaller than the debt load. This leverage is mitigated by a current ratio of 2.20, indicating that the company possesses more than twice the current assets necessary to cover its current liabilities, suggesting adequate short-term liquidity to meet obligations as they come due. Furthermore, the return metrics reveal management effectiveness challenges, with a return on equity of -147.1% reflecting the dilutive impact of losses on shareholder value, while a return on assets of 0.9% indicates that the asset base is barely generating positive returns before interest and taxes.
Valuation Assessment
Valuation multiples for Harvard Bioscience reflect the company's current earnings status, with a trailing twelve-month P/E ratio listed as N/A due to the net loss, while the forward P/E stands at 6.09, implying that the market prices the stock based on anticipated future earnings recovery rather than current performance. The price-to-book ratio is 1.59, indicating that the market values the company at a premium of approximately 59% over its net book value, a metric that can be difficult to interpret for loss-making firms but suggests some degree of goodwill or intangible asset valuation. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 0.25 and an EV/EBITDA of 7.72, suggesting the stock is priced at a quarter of its revenue and at less than eight times its earnings before interest, taxes, depreciation, and amortization, which are often attractive multiples for small-cap growth or turnaround candidates. The stock's price volatility is contextualized by its 52-week trading range between $2.80 and $9.50, meaning the current price sits at a specific point within this band, though the exact percentage deviation requires the current market price which is not provided in the facts, so the absolute range defines the investor's risk parameters. Additionally, the beta value of 1.45 indicates that the stock is expected to be 45% more volatile than the broader market, signaling that price swings will likely be amplified during periods of general market turbulence.
Growth & Income
Harvard Bioscience reported a revenue growth year-over-year of -3.3%, while earnings growth is listed as N/A due to the lack of positive earnings in the prior period for comparison. This negative revenue trajectory suggests a contraction in demand or market share, and since there are no positive earnings to compare against, the distinction between revenue and earnings growth rates cannot be made in the traditional sense of profitability expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm reinvests all available capital, including its free cash flow, back into operations or debt reduction rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined by revenue contraction and a lack of dividend income, forcing investors to rely entirely on potential future earnings turnaround or asset appreciation for returns.